Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC1679-0001 · 1 trial · 2 indications
Measured in events.
| Arm | Type | Description |
|---|---|---|
| NNC1679-0001 | EXPERIMENTAL | Participants will receive NNC1679-0001 subcutaneously. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to NNC1679-0001 s.c. |
| Name | Type | Description |
|---|---|---|
| NNC1679-0001 | DRUG | NNC1679-0001 will be administered subcutaneously. |
| Placebo | DRUG | Placebo will be administered subcutaneously. |
Inclusion Criteria: All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male or female (sex at birth) of nonchildbeari...
NNC1679-0001 is an investigational small molecule drug being developed by Novo Nordisk A/S for the treatment of type 2 diabetes mellitus. It is currently in Phase 1 clinical development and has not been approved for any indication. It is being studied in healthy volunteers and in participants with type 2 diabetes.
NNC1679-0001 is being studied as a potential treatment for type 2 diabetes mellitus. It is an investigational therapy in Phase 1 testing, so it is not yet available as a prescribed treatment. Its safety is being evaluated in healthy participants and in people with type 2 diabetes.
NNC1679-0001 is being developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the Phase 1 study evaluating the drug in healthy volunteers and participants with type 2 diabetes.
NNC1679-0001 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 program is designed to evaluate safety in healthy participants and participants with type 2 diabetes.
NNC1679-0001 is being studied in one Phase 1 trial, NCT07570992, titled a research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM. The trial is currently recruiting, is placebo-controlled and double-blind, and plans to enroll 58 participants in Austria.
The Phase 1 trial of NNC1679-0001, NCT07570992, is a randomized, double-blind, placebo-controlled study. It is recruiting 58 participants aged 18 years and older of all sexes, including healthy volunteers and people with type 2 diabetes, and is being conducted in Austria.